Zenas Biopharma, INC 8-K filings

Zenas BioPharma announced its second quarter 2026 financial results, highlighting the FDA's acceptance of the obexelimab BLA for IgG4-RD and providing updates on its clinical pipeline.

Zenas BioPharma reported Q1 2026 financial results, highlighting progress in its autoimmune disease pipeline and extended cash runway into 2029.

Zenas BioPharma, Inc. successfully completed a public offering of $200 million in convertible senior notes and 5 million shares of common stock, raising approximately $287.4 million to fund its pipeline and potential product launch.

Zenas BioPharma announced its Q4 and full-year 2025 financial results, highlighted by positive Phase 3 obexelimab data and a new $250 million debt facility.

Zenas BioPharma, Inc. has approved an Amended and Restated Short-Term Incentive Plan, effective January 1, 2026, to enhance employee motivation and retention through performance-based cash bonuses.

Zenas BioPharma announced positive Phase 3 trial results for obexelimab in IgG4-RD, paving the way for regulatory submissions and extending its cash runway through 2026.

Zenas BioPharma's Board approved a new 2026 Inducement Plan, authorizing up to 1,000,000 shares for new employee equity awards without shareholder approval.

Zenas BioPharma announced its Q3 2025 financial results, positive Phase 2 obexelimab data, significant pipeline expansion, and new funding agreements.

Zenas BioPharma announced positive Phase 2 MoonStone trial results for obexelimab in relapsing multiple sclerosis, showing a 95% reduction in new lesions.

Zenas BioPharma announced a transformative license agreement with InnoCare Pharma for three autoimmune product candidates, including a Phase 3 BTK inhibitor for MS, and a $120 million private placement financing.

Zenas BioPharma secured up to $300 million in funding from Royalty Pharma for its obexelimab program, bolstering its financial position for late-stage development and commercialization.

Zenas BioPharma announced its second quarter 2025 financial results, reporting increased losses while advancing its obexelimab clinical programs with key trial readouts expected by year-end 2025 and mid-2026.

Zenas BioPharma, Inc. held its 2025 Annual Meeting of Stockholders, resulting in the election of two Class I directors, the ratification of its independent auditor, and a reduction in the Board of Directors' size following a director's departure.

Zenas BioPharma, Inc. presented its corporate strategy and clinical pipeline for Obexelimab, a B cell inhibitor, targeting multi-billion dollar markets in IgG4-Related Disease, Relapsing Multiple Sclerosis, and Systemic Lupus Erythematosus, with significant Phase 2 and Phase 3 data expected through mid-2026.

Zenas BioPharma announced its Q1 2025 financial results, highlighting progress in clinical trials and key leadership appointments.

Zenas BioPharma reports 2024 achievements, sets 2025 goals, and announces a preliminary unaudited cash balance of $350 million as of year-end 2024.

Zenas BioPharma has released an investor presentation detailing progress in its clinical trials for obexelimab, a B-cell therapeutic, across multiple autoimmune diseases.

Zenas BioPharma announced its third quarter 2024 financial results, highlighted by the completion of its IPO and progress in clinical trials for its lead product candidate, obexelimab.

Zenas BioPharma finalized its initial public offering, leading to the filing of a second restated certificate of incorporation and amended bylaws.